RenovoRx RNXT Insider Ownership

NASDAQ RNXT

$1.25 +0.05 (+4.58%)

As of: Oct 21, 2026 · 1:45 PM EDT

Insider Holdings by Owner

1.44Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

5.56%

▲+0.169% pp QoQ

Shares Held by Insiders

2.63Mn

filed for Sep 2026

▲+3.14% QoQ

Shares Outstanding

47.30Mn

47,298,148 shares

Direct Holdings

1.23Mn

Indirect: 1.40Mn

Net Shares Traded (QoQ)

+80.00K

net buying in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 5, 2026

Over the past 12 months, RenovoRx insiders bought at least $84,427 of stock on the open market (230.22K shares), and made no open-market sales.

Counted by insider, open-market buying of RNXT stock in the past 12 months came from 4 insiders, with no insider selling.
Among RenovoRx's insiders, Ramtin Agah (Chief Medical Officer) was the largest open-market buyer over the past 12 months, purchasing $55,968 of stock (64K shares), most recently on January 21, 2026.
The latest open-market trade in RNXT stock by an insider was a purchase of 25K shares for $19,690 by Mark Voll (Chief Financial Officer) on May 19, 2026.
Apart from open-market trades, RNXT insiders received 172.38K shares in stock awards in the past 12 months.
Per Business Quant data, RenovoRx insiders hold 2.63Mn shares in total based on their latest Form 4 filings, or 5.56% of the 47.3Mn shares outstanding; that total is up 3.14% from 2.55Mn shares at the end of Q2 2026 and up 19.37% from 2.2Mn shares at the end of Q3 2025.
Of the 2.63Mn shares held by RenovoRx insiders, 1.23Mn shares (46.90%) are held directly and 1.4Mn shares (53.10%) indirectly, through trusts, partnerships, family members and other entities.
Holdings in RenovoRx stock are reported by 7 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
RNXT's three largest insider shareholders, per their latest Form 4 filings, are Ramtin Agah (Chief Medical Officer, 1.77Mn shares), Shaun Bagai (Chief Executive Officer, 364.34K shares) and Mark Voll (Chief Financial Officer, 319.58K shares).
The holding of Ramtin Agah makes up 67.49% of all shares held by RenovoRx insiders.
In the last 12 months, 22 Form 4 filings with transactions in RNXT stock came from 8 insiders.
The insider data for RNXT reflects Form 4 filings through October 2, 2026.

Form 4 Holdings

Insiders Holding RNXT

Insiders 8

Shares held 1.44Mn

Of outstanding 3.04%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Ramtin Agah	Chief Medical Officer	798,460	0	798,460	55.5%	22 Jan, 2026
2	Shaun Bagai	Chief Executive Officer	0	313,357	313,357	21.8%	24 Mar, 2026
3	Mark Voll	Chief Financial Officer	222,380	0	222,380	15.4%	15 Sep, 2026
4	Robert J. Spiegel	Director	40,983	0	40,983	2.8%	30 Jan, 2024
5	K. Angela Macfarlane	Director	40,983	0	40,983	2.8%	30 Jan, 2024
6	Ron Kocak	Vp Controller And Pao	12,595	0	12,595	0.9%	10 Apr, 2025
7	Laurence Marton	Director	0	9,720	9,720	0.7%	24 Mar, 2026
8	Angela Nelms	Chief Operating Officer	1,100	0	1,100	0.1%	04 Oct, 2023

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

113 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
01 Oct, 2026	K. Angela Macfarlane	Director	Acquired A	55,924	$0.00	$0	55,924	Direct
01 Oct, 2026	Una S Ryan	Director	Acquired A	55,924	$0.00	$0	55,924	Direct
01 Oct, 2026	Laurence Marton	Director	Acquired A	55,924	$0.00	$0	55,924	Direct
01 Oct, 2026	Robert J. Spiegel	Director	Acquired A	55,924	$0.00	$0	55,924	Direct
10 Sep, 2026	Mark Voll	Chief Financial Officer	Acquired A	80,000	$0.00	$0	222,380	Direct
19 May, 2026	Mark Voll	Chief Financial Officer	Acquired P	25,000	$0.79	$19.69K	142,380	Direct
03 Apr, 2026	Shaun Bagai	Chief Executive Officer	Acquired A	946,107	$0.00	$0	946,107	Direct
03 Apr, 2026	Mark Voll	Chief Financial Officer	Acquired A	80,000	$0.00	$0	117,380	Direct
03 Apr, 2026	Ramtin Agah	Chief Medical Officer	Acquired A	621,727	$0.00	$0	621,727	Direct
03 Apr, 2026	Leesa Gentry	Chief Clinical Officer	Acquired A	128,550	$0.00	$0	128,550	Direct
25 Mar, 2026	Mark Voll	Chief Financial Officer	Acquired A	12,380	$0.00	$0	37,380	Direct
20 Mar, 2026	Laurence Marton	Director	Acquired P	9,720	—	—	9,720	Indirect
20 Mar, 2026	Mark Voll	Chief Financial Officer	Acquired P	97,200	—	—	97,200	Indirect
20 Mar, 2026	Shaun Bagai	Chief Executive Officer	Acquired P	24,300	—	—	313,357	Indirect
20 Mar, 2026	Laurence Marton	Director	Acquired P	4,860	—	—	4,860	Indirect
20 Mar, 2026	Mark Voll	Chief Financial Officer	Acquired P	48,600	—	—	48,600	Indirect
20 Mar, 2026	Shaun Bagai	Chief Executive Officer	Acquired P	12,150	—	—	12,150	Indirect
21 Jan, 2026	Ramtin Agah	Chief Medical Officer	Acquired P	10,000	$1.00	$9.98K	798,460	Direct
31 Dec, 2025	Ramtin Agah	Chief Medical Officer	Acquired P	9,795	$0.86	$8.42K	788,460	Direct
30 Dec, 2025	Ramtin Agah	Chief Medical Officer	Acquired P	205	$0.83	$169	778,665	Direct

Showing 1 to 20 of 113 transactions